Biosimilar Regulation Headaches From Morocco To Pakistan
Executive Summary
Delegates at the recent pre-ICDRA conference heard about the issues dogging the regulation of biosimilar medicines in the Eastern Mediterranean Region, including unfamiliarity with the comparability exercise and a lack of expertise and resources in this area. The question of a "global comparator product" was also raised.
You may also be interested in...
Biosimilar Sponsors Say Pharmacokinetic Bridging Studies Should Be The Exception, Not The Norm
US FDA guidance runs risk of creating de facto requirement for bridging studies when a biosimilar applicant seeks to use comparative data involving a foreign reference product, Novartis says; IGBA, AAM urge agency adopt a ‘global comparator’ approach that would eliminate the need for clinical bridging studies between US and foreign reference biologics.
WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars
Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.